Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing-remitting multiple sclerosis patients

Multiple Sclerosis

Volumn 11, Issue 3, 2005, Pages 251-260

  Moldovan, I R ^a   Rudick, R A ^a   Cotleur, A C ^a   Born, S E ^a   Lee, J C ^a   Karafa, M T ^a   Pelfrey, Clara M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

ELISPOT; IFN ; IL 10; Longitudinal cytokine reactivity; Multiple sclerosis; Myelin basic protein; Proteolipid protein

Indexed keywords

AMINO ACID; BETA1A INTERFERON; CYTOKINE; GADOLINIUM; MYELIN; MYELIN BASIC PROTEIN; PROTEOLIPID PROTEIN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; BRAIN DISEASE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOREACTIVITY; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECURRENT DISEASE;

ADOLESCENT; ADULT; AUTOANTIGENS; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN BASIC PROTEINS; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH;

EID: 20144364415     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1165oa     Document Type: Article

References (36)

1. Raine CS, Scheinberg LC. On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol 1988; 20: 189-201.
2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-87.
3. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968-72.
4. Valli A, Sette A, Kappos L, Oseroff C, Sidney J, Miescher G et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993; 91: 616-28.
5. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990; 247: 718-21.
6. Johnson D, Hafler DA, Fallis RJ, Lees MB, Brady RO, Quarles RH et al. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol 1986; 13: 99-108.
7. Kerlero DR, Hoffman M, Mendel I, Yust I, Kaye J, Bakimer R et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 1997; 27: 3059-69.
8. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155-57.
9. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997; 99: 1682-90.
10. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996; 8: 831-36.
11. Perry LL, Barzaga-Gilbert E, Trotter JL. T cell sensitization to proteolipid protein in myelin basic protein-induced relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1991; 33: 7-15.
12. Miller SD, Tan LJ, Pope L, McRae BL, Karpus WJ. Antigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis. Int Rev Immunol 1992; 9: 203-22.
13. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993; 14: 203-208.
14. Lisak RP, Zweiman B, Waters D, Korpowski H, Pleasure DE. Cell-mediated immunity to measles, myelin basic protein, and central nervous system extract in multiple sclerosis. A longitudinal study employing direct buffy coat migration inhibition assays. Neurology 1978; 28: 798-803.
15. Calabresi PA, Fields NS, Farnon EC, Frank JA, Bash CN, Kawanashi T et al. ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J Neuroimmunol 1998; 85: 212-19.
16. Pender MP, Csurhes PA, Greer JM, Mowat PD, Henderson RD, Cameron KD et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000; 165: 5322-31.
17. Hellings N, Gelin G, Medaer R, Bruckers L, Palmers Y, Raus J et al. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. J Neuroimmunol 2002; 126: 143-60.
18. Arbour N, Holz A, Sipe JC, Naniche D, Romine JS, Zyroff J et al. A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J Neuroimmunol 2003; 137: 197-209.
19. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-704.
20. Fisher E, Cothren RM, Tkach J, Masaryk TJ, Cornhill JF. Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking. SPIE Medical Imaging 1997; 3034: 19-25.
21. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 2000; 165: 1641-51.
22. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, Pelfrey CM. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol 2003; 141: 132-40.
23. Pelfrey CM, Trotter JL, Tranquill LR, McFarland HF. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients. J Neuroimmunol 1993; 46: 33-42.
24. Pelfrey CM, Trotter JL, Tranquill LR, McFarland HF. Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients. J Neuroimmunol 1994; 53: 153-61.
25. Tuohy VK. Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review. Neurochem Res 1994; 19: 935-44.
26. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997; 120: 1447-60.
27. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983; 81: 435-40.
28. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000; 123: 508-18.
29. Hellings N, Baree M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC et al. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 2001; 63: 290-302.
30. Correale J, de los Milagros Bassani Molinas. Time course of T-cell responses to MOG and MBP in patients with clinically isolated syndromes. J Neuroimmunol 2003; 136: 162-71.
31. Vergelli M, Mazzanti B, Traggiai E, Biagioli T, Ballerini C, Parigi A et al. Short-term evolution of autoreactive T cell repertoire in multiple sclerosis. J Neurosci Res 2001; 66: 517-24.
32. Adorini L, Muller S, Cardinaux F, Lehmann PV, Falcioni F, Nagy ZA. In vivo competition between self peptides and foreign antigens in T-cell activation. Nature 1988; 334: 623-25.
33. Gammon G, Geysen HM, Apple RJ, Pickett E, Palmer M, Ametani A et al. T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med 1991; 173: 609-17.
34. Targoni OS, Lehmann PV. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 1998; 187: 2055-63.
35. Tuohy VK, Yu M, Yin L, Kawczak JA, Johnson JM, Mathisen PM et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998; 164: 93-100.
36. Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel PR. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 1999; 13: 11-20.